Alto Neuroscience, Inc. (ANRO)

USD 3.64

(-3.96%)

Operating Income Summary of Alto Neuroscience, Inc.

  • Alto Neuroscience, Inc.'s latest annual operating income in 2023 was -37.8 Million USD , down -29.52% from previous year.
  • Alto Neuroscience, Inc.'s latest quarterly operating income in 2024 Q1 was -14.38 Million USD , down -22.28% from previous quarter.
  • Alto Neuroscience, Inc. reported an annual operating income of -29.19 Million USD in 2022, down -142.14% from previous year.
  • Alto Neuroscience, Inc. reported an annual operating income of -12.05 Million USD in 2021, down 0.0% from previous year.
  • Alto Neuroscience, Inc. reported a quarterly operating income of -18.34 Million USD for 2024 Q2, down -27.49% from previous quarter.
  • Alto Neuroscience, Inc. reported a quarterly operating income of -9.12 Million USD for 2023 Q2, down -26.72% from previous quarter.

Annual Operating Income Chart of Alto Neuroscience, Inc. (2023 - 2021)

Historical Annual Operating Income of Alto Neuroscience, Inc. (2023 - 2021)

Year Operating Income Operating Income Growth
2023 -37.8 Million USD -29.52%
2022 -29.19 Million USD -142.14%
2021 -12.05 Million USD 0.0%

Peer Operating Income Comparison of Alto Neuroscience, Inc.

Name Operating Income Operating Income Difference
ADC Therapeutics SA -165.98 Million USD 77.222%
Annovis Bio, Inc. -45.03 Million USD 16.045%
Biohaven Pharmaceutical Holding Company Ltd. -436.05 Million USD 91.329%
Ginkgo Bioworks Holdings, Inc. -864.4 Million USD 95.626%
Nuvation Bio Inc. -99.82 Million USD 62.124%
Nuvation Bio Inc. -99.82 Million USD 62.124%
Arcus Biosciences, Inc. -340 Million USD 88.88%
Theriva Biologics, Inc. -21.43 Million USD -76.422%
Zymeworks Inc. -138.05 Million USD 72.613%